Implications physiopathologiques et cliniques des recepteurs AT(1)/AT(2) de l'angiotensine II dans l'hypertension essentielle. [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension]

Détails

ID Serval
serval:BIB_42A037B280D5
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Implications physiopathologiques et cliniques des recepteurs AT(1)/AT(2) de l'angiotensine II dans l'hypertension essentielle. [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension]
Périodique
Drugs
Auteur(s)
Burnier  M.
ISSN
0012-6667 (Print)
Statut éditorial
Publié
Date de publication
2002
Volume
62 Spec No 1
Pages
21-9
Notes
English Abstract
Journal Article
Research Support, Non-U.S. Gov't
Review
Résumé
The renin-angiotensin system exerts a cardinal role in the maintenance of blood pressure and in the regulation of water and sodium excretion through its multiple effects on the vasculature, the kidneys, the heart, the adrenal glands and the brain. Over the last 30 years, blockade of the renin-angiotensin cascade with angiotensin converting enzyme (ACE) inhibitors has proved to be a major advance in the treatment of hypertension and the prevention of its cardiovascular complications. The recent development of specific, orally active angiotensin AT(1) receptor antagonists has provided further insights into the role of the various angiotensin receptor subtypes in the regulation of blood pressure. Even more importantly, these new specific antagonists have provided the opportunity to effectively block the renin-angiotensin system in hypertensive patients with an efficacy comparable to that of other antihypertensive agents but with a tolerability profile similar to that of placebo. Numerous clinical studies have now demonstrated the potential benefits of these agents in the management of essential hypertension. We now need to know whether these agents are capable of reducing the cardiovascular morbidity and mortality associated with hypertension. To this purpose, several large clinical trials are ongoing and we are eager to read their results.
Mots-clé
Angiotensin-Converting Enzyme Inhibitors/*pharmacology/therapeutic use Antihypertensive Agents/*pharmacology/therapeutic use Cardiovascular Diseases/epidemiology/physiopathology Humans Hypertension/drug therapy/*physiopathology Receptor, Angiotensin, Type 1 Receptor, Angiotensin, Type 2 Receptors, Angiotensin/*antagonists & inhibitors/metabolism Renin-Angiotensin System/*drug effects/physiology
Pubmed
Web of science
Création de la notice
25/01/2008 13:55
Dernière modification de la notice
03/03/2018 16:38
Données d'usage